We are live on
!
Find out more
LC
Lindbrook Capital Portfolio holdings
AUM
$1.08B
1-Year Est. Return
10.14%
This Fund
S&P 500
This Quarter
Est. Return
+7.65%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
–
AUM
$939M
AUM Growth
+$86.2M
(+10%)
Cap. Flow
+$29.6M
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
46.18%
Holding
2,925
New
150
Increased
988
Reduced
857
Closed
215
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total International Stock ETF
VXUS
|
+$5.37M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.7M |
| 3 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$2.54M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$2.12M |
| 5 |
NVIDIA
NVDA
|
+$1.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.88M |
| 2 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$4.62M |
| 3 |
Oaktree Specialty Lending
OCSL
|
+$825K |
| 4 |
MGI
MoneyGram International, Inc. New
MGI
|
+$627K |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$562K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.18% |
| 2 | Technology | 15.3% |
| 3 | Healthcare | 6.27% |
| 4 | Consumer Discretionary | 3.61% |
| 5 | Industrials | 3.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
STAAR Surgical
STAA
$1.21B
| $4.52K | ﹤0.01% |
86
-133
| -61% | -$8.1K |
|
1852
Manitowoc
MTW
$675M
| $4.52K | ﹤0.01% |
240
+73
| +44% | +$1.18K |
|
1853
Warrior Met Coal
HCC
$4.86B
| $4.52K | ﹤0.01% |
116
-160
| -58% | -$5.79K |
|
1854
Carvana
CVNA
$77.9B
| $4.51K | ﹤0.01% |
870
| – | – |
|
1855
GATX Corp
GATX
$6.27B
| $4.51K | ﹤0.01% |
35
| – | – |
|
1856
KBR
KBR
$4.8B
| $4.49K | ﹤0.01% |
69
| – | – |
|
1857
Mitek Systems
MITK
$834M
| $4.48K | ﹤0.01% |
+413
| New | +$4.04K |
|
|
ORC
1858
Orchid Island Capital
ORC
$1.31B
| $4.47K | ﹤0.01% |
432
| – | – |
|
1859
KeyCorp
KEY
$24.4B
| $4.46K | ﹤0.01% |
483
-71
| -13% | -$741 |
|
1860
Strategy Inc
MSTR
$38.4B
| $4.45K | ﹤0.01% |
130
| – | – |
|
1861
US Foods
USFD
$24B
| $4.44K | ﹤0.01% |
101
+12
| +13% | +$476 |
|
1862
Pacific Biosciences
PACB
$370M
| $4.44K | ﹤0.01% |
334
+34
| +11% | +$413 |
|
|
HDSN
1863
Hudson Technologies
HDSN
$235M
| $4.43K | ﹤0.01% |
461
+275
| +148% | +$2.39K |
|
1864
Vanda Pharmaceuticals
VNDA
$302M
| $4.43K | ﹤0.01% |
673
+561
| +501% | +$3.6K |
|
1865
CACI
CACI
$14.2B
| $4.43K | ﹤0.01% |
13
| – | – |
|
1866
Paylocity
PCTY
$7.98B
| $4.43K | ﹤0.01% |
24
-9
| -27% | -$1.65K |
|
1867
Chegg
CHGG
$102M
| $4.42K | ﹤0.01% |
498
-884
| -64% | -$10.7K |
|
1868
N-able
NABL
$940M
| $4.41K | ﹤0.01% |
306
| – | – |
|
1869
Donegal Group Class A
DGICA
$714M
| $4.4K | ﹤0.01% |
305
| – | – |
|
1870
Arvinas
ARVN
$572M
| $4.39K | ﹤0.01% |
177
+58
| +49% | +$1.49K |
|
1871
Stoke Therapeutics
STOK
$2.11B
| $4.38K | ﹤0.01% |
412
-123
| -23% | -$1.31K |
|
|
FRC
1872
DELISTED
First Republic Bank
FRC
| $4.36K | ﹤0.01% |
7,932
-13,986
| -64% | -$171K |
|
1873
Forward Air
FWRD
$654M
| $4.35K | ﹤0.01% |
41
-4
| -9% | -$409 |
|
|
FOLD
1874
DELISTED
Amicus Therapeutics
FOLD
| $4.35K | ﹤0.01% |
346
+77
| +29% | +$914 |
|
1875
Valaris
VAL
$5.47B
| $4.34K | ﹤0.01% |
69
-5
| -7% | -$301 |
|
Similar funds
SBIA
CHP
MW
TAM
SIA
CIG
CCM
WCF
Lindbrook Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Lindbrook Capital held 2,925 positions worth $939M, up 10% from $853M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Lindbrook Capital deployed $29.6M of net new capital in Q2 2023, opening 150 new positions and adding to 988 existing holdings. Its largest new stake was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $6.88M trimmed.
- Lindbrook Capital's largest Q2 2023 buy was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
- Lindbrook Capital added most to Vanguard Total International Stock ETF in Q2 2023, an estimated $5.37M increase.
- Lindbrook Capital's biggest Q2 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $6.88M.
- Lindbrook Capital fully exited MoneyGram International, Inc. New in Q2 2023, selling an estimated $627K.
- Lindbrook Capital's ten largest holdings make up 46% of its $939M portfolio in Q2 2023.
- Lindbrook Capital opened 150 new positions and closed 215 in Q2 2023.
- Lindbrook Capital's portfolio value rose 10% quarter-over-quarter to $939M.
Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.